TY  - THES
N2  - Due to the complexity of BCR/ABL-independent TKI resistance, a central question is whether relapse acts through the canonical BCR/ABL CML pathways seen in dependent cases, or through a different set of genes and pathways. To answer this question, both RNA-seq and Whole Exome Sequencing data was collected and analyzed as part of a large retrospective study of CML patients with acquired resistance to imatinib and other related TKI inhibitors. RNA-seq and Whole Exome sequencing are both next generation sequencing approaches which allow for the high-throughput, cost-effective characterization of an individual's entire mRNA transcript profile (RNAseq) or protein coding region of the genome (WES)[15]. This study was comprised of 244 samples (123 WES, 121 RNAseq) collected from seven different clinical locations across the United States and Europe. These samples represented 130 unique patients, 70 of which had samples collected for both data types, 36 for WES only, and 24 for RNAseq only.
DO  - 10.6083/m4n58kw5
DO  - DOI
AB  - Due to the complexity of BCR/ABL-independent TKI resistance, a central question is whether relapse acts through the canonical BCR/ABL CML pathways seen in dependent cases, or through a different set of genes and pathways. To answer this question, both RNA-seq and Whole Exome Sequencing data was collected and analyzed as part of a large retrospective study of CML patients with acquired resistance to imatinib and other related TKI inhibitors. RNA-seq and Whole Exome sequencing are both next generation sequencing approaches which allow for the high-throughput, cost-effective characterization of an individual's entire mRNA transcript profile (RNAseq) or protein coding region of the genome (WES)[15]. This study was comprised of 244 samples (123 WES, 121 RNAseq) collected from seven different clinical locations across the United States and Europe. These samples represented 130 unique patients, 70 of which had samples collected for both data types, 36 for WES only, and 24 for RNAseq only.
AD  - Oregon Health and Science University
T1  - Batch effect detection and network analysis in BCR/ABL-independent CML imatinib resistance
DA  - 2017
AU  - Therneau, Adam
L1  - https://digitalcollections.ohsu.edu/record/7649/files/Therneau.Adam.2017.pdf
PB  - Oregon Health and Science University
PB  - Oregon Health and Science University
PY  - 2017
ID  - 7649
L4  - https://digitalcollections.ohsu.edu/record/7649/files/Therneau.Adam.2017.pdf
KW  - Precision Medicine
KW  - Drug Resistance
KW  - Leukemia
KW  - Computational Biology
KW  - Molecular Targeted Therapy
KW  - Algorithms
TI  - Batch effect detection and network analysis in BCR/ABL-independent CML imatinib resistance
Y1  - 2017
L2  - https://digitalcollections.ohsu.edu/record/7649/files/Therneau.Adam.2017.pdf
LK  - https://digitalcollections.ohsu.edu/record/7649/files/Therneau.Adam.2017.pdf
UR  - https://digitalcollections.ohsu.edu/record/7649/files/Therneau.Adam.2017.pdf
ER  -